Sorafenib. ICORG 06-41, V4

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating patients with relapsed esophageal cancer and/or stomach cancer.

Detailed Description
-----------------
OBJECTIVES: Primary To determine the disease control rate (complete response, partial response, and stable disease) of sorafenib tosylate after 4 months in patients with relapsed esophageal or gastric adenocarcinoma previously treated with platinum-based chemotherapy. Secondary To determine the progression-free survival of patients treated with this drug. To determine the overall survival of patients treated with this drug. To determine the time to tumor progression in patients treated with this drug. To determine the objective response rate in patients treated with this drug. To determine the tolerability and toxicity in patients treated with this drug. To assess biomarkers associated with response/resistance to therapy. (exploratory) OUTLINE: This is a multicenter study. Patients receive oral sorafenib tosylate twice a day on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood and tumor samples may be collected periodically and analyzed for biological markers. After completion of study treatment, patients are followed up periodically.

Official Title
-----------------
Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients

Conditions
-----------------
Esophageal Cancer, Gastric Cancer

Intervention / Treatment
-----------------
* Drug: sorafenib tosylate
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed esophageal and/or gastric adenocarcinoma Relapsed or progressed disease after prior platinum-based chemotherapy and not a suitable candidate for radical therapy At least 1 unidimensionally measurable lesion as assessed by RECIST criteria No uncontrolled, symptomatic brain metastases Patients with intracranial bleeding into metastases allowed provided the disease is well-controlled and not undergoing acute steroid therapy or taper (chronic steroid therapy allowed provided the dose is stable for 1 month prior to and following screening radiographic studies) PATIENT CHARACTERISTICS: ECOG performance status 0-2 Life expectancy ≥ 2 months Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Total bilirubin ≤ 1.5 times upper limit of normal (ULN) ALT/AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement) Alkaline phosphatase ≤ 2.5 times ULN (≤ 4 times ULN for patients with bony involvement) INR ≤ 1.5 aPTT normal Creatinine ≤ 1.5 times ULN Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier method contraception prior to and during study therapy (men and women) and for 3 months after completion of study therapy (men) Not planning pregnancy within 6 months after completion of study therapy No history of cardiac disease, including any of the following: NYHA class III-IV congestive heart failure Active coronary artery disease (myocardial infarction more than 6 months prior to study entry allowed) Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) No uncontrolled hypertension (systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg, despite optimal medical management) No known HIV infection or chronic hepatitis B or C No active, clinically serious infections > CTCAE grade 2 No thrombotic or embolic events (e.g., cerebrovascular accident including transient ischemic attacks within the past 6 months) No pulmonary hemorrhage or bleeding event > CTCAE grade 2 within the past 4 weeks No other hemorrhage or bleeding event > CTCAE grade 3 within the past 4 weeks No serious, nonhealing wound, ulcer (apart from the tumor), or bone fracture No evidence or history of bleeding diathesis or coagulopathy No current signs or symptoms of severe progressive or uncontrolled hepatic, hematological, renal, endocrine, pulmonary, or cardiac disease No known or suspected allergy to sorafenib or any agent given in the course of this trial No previous cancer that is distinct in primary site or histology from esophago-gastric junction cancer except for carcinoma in situ of the cervix, treated basal cell carcinoma, superficial bladder tumors [Ta and Tis], or any cancer curatively treated > 3 years prior to study entry No concurrent cancer that is distinct in primary site or histology from esophago-gastric cancer No substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results No condition that impairs the patient's ability to swallow whole pills No malabsorption condition No seizure disorder requiring medication (e.g., steroids or antiepileptics) No familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule No significant traumatic injury within the past 4 weeks PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 3 weeks since prior local radiotherapy At least 3 weeks since prior biologic response modifiers (e.g., G-CSF) G-CSF and other hematopoietic growth factors allowed in the management of acute toxicity (e.g., febrile neutropenia) when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction Concurrent chronic erythropoietin allowed provided no dose adjustment is undertaken within 2 months prior to the study or during the study At least 4 weeks since prior major surgery or open biopsy At least 4 weeks since prior and no concurrent radiotherapy Prior or concurrent palliative radiotherapy to symptomatic disease sites allowed (unless the site to be irradiated is one of the target lesions used for response assessment) At least 4 weeks since prior and no concurrent anticancer chemotherapy, immunotherapy, or hormonal therapy (except bisphosphonates) At least 30 days since prior and no concurrent investigational drug therapy At least 5 weeks since prior and no concurrent mitomycin C or nitrosoureas At least 4 months since prior autologous bone marrow transplant or stem cell rescue No history of organ allograft No prior licensed or investigational tyrosine kinase inhibitor or antiangiogenic agent (e.g., sunitinib or bevacizumab) No prior sorafenib tosylate No prior licensed or investigational drug treatment that targets the RAS, VEGF, VEGFR, or EGFR pathway No concurrent rifampin or St. John wort No concurrent therapeutic anticoagulation with vitamin K antagonists (e.g., warfarin, heparins, or heparinoids) Low-dose warfarin (1 mg by mouth once a day) allowed provided INR is < 1.5 Low-dose aspirin allowed No concurrent renal dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sorafenib 400mg bd, p.o, continuously<br> | Drug: sorafenib tosylate<br> <br> Other: laboratory biomarker analysis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease control rate after 4 months |  | After 4 months of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression free survival and overall survival probabilities over time will be estimated using Kaplan-Meier plots. Their medians with their confidence intervals will be also presented. Progression Free Survival is measured from first treatment until the date of disease progression or death, whichever is reported first. Subjects who do not progress or die at the time of the analysis will be censored at the day of their last tumour assessment. | Ongoing | 
| Overall survival | Overall survival is measured from the date of first treatment to the date of the subject's death. If the subject is alive or the vital status is unknown, the date of death will be censored at the date that the subject is last known to be alive. | Ongoing | 
| Time to tumor progression |  | Ongoing | 
| Objective response rate | The study has been designed to use the disease control rate at 4 months on treatment as the primary endpoint. | Response would be assessed by appropriate imaging (e.g. CT) every 8 weeks. | 
| Tolerability and toxicity | Patients would be assessed for toxicity according to NCI CTC version 3. | Ongoing for duration of treatment and 30 day follow up. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenocarcinoma of the esophagus, recurrent esophageal cancer, recurrent gastric cancer, adenocarcinoma of the stomach